Introduction
Fungal infections are a major complication in hematologic and neoplastic patients undergoing prolonged chemotherapy and often cause severe morbidity and mortality. In humans, Aspergillus fumigatus and Candida albicans are important fungal pathogens frequently causing severe infections with invasive growth in immunocompromised patients. 1 Unfortunately, the use of classic antifungal drugs is unsuccessful in many of these patients. Retinoic acid -the biologically active metabolite of vitamin A -controls the normal immune system development as a modulator of both innate and adaptive immune responses. 2 Vitamin A is a nutrient obtained through the diet either as provitamin-A (carotenoids) or as preformed vitamin A (retinol and retinyl esters). After its transport through the cytoplasmic binding with specific receptors, liver dehydrogenases convert retinol into retinoic acid, its biologically active metabolite. [3] [4] [5] [6] [7] Over the last decades, an increasing effort has been devoted to better define the involvement in the regulation of immune response, since vitamin A deficiency has been associated with an increased susceptibility to severe infectious diseases. 8, 9 The adding of all-trans retinoic acid (ATRA) to the therapy of acute promyelocytic leukemia resulted in a lower incidence of total episodes of fungemias in the patients. 10 Recent studies support the hypothesis that efficacy of vitamin A or ATRA alone or in combination with other drugs is related to its capacity to stimulate both innate and the adaptive immunity, in particular the monocyte-mediated immune response. 4, [10] [11] [12] We recently reported that tazarotene, a retinoic acid derivative, inhibits Tricophyton and C. albicans growth in vitro and a topical treatment with 0.1% tazarotene gel is effective in lateral onychomycosis. 13 Since the contribution of inflammatory response is quite limited in the affected nail, we hypothesized that the beneficial effects of retinoids derive from a direct fungistatic activity.
In comparison with tazarotene, ATRA offers the advantage of systemic therapy and is widely used in many patients safely. We aimed to investigate the efficacy of ATRA against opportunistic fungal pathogens such as A. fumigatus and C. albicans. 
Methods

Fungal culture conditions
evaluation of fungistatic activity
The development of A. fumigatus and C. albicans was followed using an optical microscope (Carl Zeiss Meditec AG, Jena, Germany) with a 40× magnification objective lens. Microscopic images were recorded after 8 and 4 hours of incubation with ATRA at 37°C for A. fumigatus conidial swelling and C. albicans yeast cell germination, respectively.
Results
Light optical microscopy revealed that, at the earliest time point (8 hours) in the presence of ATRA (1 mM), A. fumigatus conidia did not swell and remained similar in shape and size to the resting ones ( Figure 1B) . On the contrary, as shown in Figure 1A , most of the control untreated conidia (~80%) were swollen and some developed short germ tube similar to those observed in the ATRA-treated cultures of nonsynchronized population of A. fumigatus at doses 1 mM ( Figure 1C ). After more prolonged incubation (24 hours), all control and ATRA-treated conidia at doses 1 mM were swollen and produced a germ tube (data not shown). ATRA at 1 and 0.5 mM also inhibited germination and hyphal outgrowth of C. albicans (Figure 1E and F). Instead, control untreated yeast cells developed germ tube and subsequently hyphal growth ( Figure 1D ). Doses of ATRA 0.5 mM did not affect the ability of C. albicans to germinate ( Figure 1G ). The inhibitory effect of ATRA on the germination of A. fumigatus and C. albicans was maintained and examined at a later time point (day 7). These data suggested that the fungistatic activity of ATRA at 0.5-1 mM concentration was obtained without any adverse effects on A. fumigatus conidia and C. albicans yeast, since their viability was 90% as assessed by trypan blue. Similar results were observed at other time points (data not shown). To confirm the vitality of A. fumigatus and C. albicans after exposure to higher (0.5-1 mM) doses, conidia and yeast cells were harvested, washed after 7 days, and again cultured in the absence of ATRA. A. fumigatus conidia and C. albicans yeasts were able to germinate into hyphae within 24 hours (data not shown), again supporting the fungistatic activity of ATRA in vitro.
Discussion
Our results documented the fungistatic activity of ATRA at 0.5-1 mM concentration on A. fumigatus and C. albicans. ATRA offers the opportunity for systemic therapy against opportunistic fungal pathogens such as A. fumigatus and C. albicans. Despite an increasing interest in the immunomodulatory role of ATRA, its specific role in the immune response to fungal infections was never explored. Our study is the first evidence of a direct and high fungistatic activity of ATRA against A. fumigatus and C. albicans. Till now, several in vitro studies highlighted the function of vitamin A as an important factor for immune system development and a modulator of the innate and the adaptive immune response. [6] [7] [8] [9] As a matter of fact, vitamin A regulates the development of B lymphocytes and immunoglobulin production. 14 Retinoic acid also shows specific immunomodulatory activities. In T lymphocytes, retinoic acid attenuated the Th1-associated gene expression and skewed the immune response toward a Th2 profile. 15 Retinoic acid also modulated the production of LPS-induced cytokines and/or chemokines in monocytes, macrophages, and dendritic cells. 16, 17 Moreover, ATRA induced proliferative arrest in nonmyeloid mesenchymal cells. 18, 19 ATRA has been shown to stimulate the differentiation of myeloid-derived suppressor cells to dendritic cells and macrophages. At therapeutic concentrations, ATRA could substantially drop the number of myeloid-derived suppressor cells in tumor-bearing mice and in patients with cancer, thus improving their antigen-specific response. 20, 21 Lei et al 11 hypothesized that ATRA treatment, alone and in combination with an 8-aminoquinoline primaquine, can push lung myeloid-derived suppressor cells to differentiate in functional macrophages helping to clear pneumonia from the Pneumocystis carinii infection. Klassert et al 12 recently reported the effects of ATRA on the immune response of human monocytes during C. albicans infection. The authors documented an immunomodulatory effect of ATRA leading to a highly significant suppression of the fungi-induced expression of TNFα, IL6, and IL12 at both the transcriptional and posttranslational levels. 12 The effectiveness of ATRA and its possible toxicity can be easily monitored in the blood. Our results in vitro are already widely proven in the clinical practice since patients affected by promyelocytic leukemia were treated with ATRA, they were less subjected to systemic infections, with a more preserved immunological profile. 10 The adjuvant application of ATRA might also be useful in the treatment and/ or prevention of systemic mycoses in immunocompromised patients. Therefore, the discovery of a direct fungistatic activity associated with its reported immunomodulatory properties makes ATRA an excellent candidate for new and efficient antifungal strategies. ATRA may be administered alone or in combination with lower doses of conventional antimycotic agents, thus reducing their side effects. Although the therapeutic systemic use of ATRA as an adjuvant for antifungal therapies requires further validation in preclinical models, the considerable health burden represented by invasive mycosis and the emerging multidrug resistance justifies every effort directed to the development of new therapeutic solutions.
